

## Product News

### **Niacin and Niacinamide Confirmed As Feed Additives**

Basel, Schweiz, 18 July 2013 – On July 4th, the European Commission published Regulation EC No 642/2013 confirming the authorization of Niacin and Niacinamide as feed additives. Lonza has submitted its dossier for Niacin and Niacinamide in 2010. It has been reviewed by the European Food Safety Authority (EFSA) and Niacin and Niacinamide are now reconfirmed to be authorized as feed additives for all animal species.

For more than 40 years, Lonza has been the global leader in vitamin B3 production specializing in both Niacin (nicotinic acid) and Niacinamide. Currently, Lonza operates three vitamin B3 plants in Europe and China. To support future growth initiatives, a new vitamin B3 manufacturing facility is under construction at Lonza's cutting edge life-sciences campus in Nansha, China. As the world's largest supplier of vitamin B3 to the global feed and food industry, Lonza has always been at the forefront of regulatory compliance and quality.

Lonza's commitment to the global feed industry is the same today as it was in 1971: to be the global leader in vitamin B3 production. Over the past four decades, we have invested to align production with market, environmental and quality demands to guarantee that we can serve our customers' ever growing and changing needs.

#### **About Lonza**

Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Products and services span its customers' needs from research to final product manufacture. It is the global leader in the production and support of chemical and biological active pharmaceutical ingredients. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. Lonza is also the world leader in microbial control providing innovative, chemistry-based and related solutions to destroy or to selectively inhibit the growth of harmful microorganisms. Its activities encompass the areas of water treatment, personal care, health and hygiene, industrial preservation, materials protection, and wood treatment. In addition, Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Furthermore, the company is a leading provider of value chemical and biotech ingredients to the nutrition and agro markets.

Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange and secondary listed on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Lonza is not subject to the SGX-ST's continuing listing requirements. Lonza is subject to the listing rules of the SIX Swiss Exchange, which do not have specific requirements equivalent to the listing rules of the SGX-ST in respect of interested person transactions, acquisition and realizations, and delisting. In 2012, the company had sales of CHF 3.925 billion. Further information can be found at [www.lonza.com](http://www.lonza.com).

Nutrition

**Lonza**

Lonza Ltd  
Muenchensteinerstrasse 38  
CH-4002 Basel  
[www.lonza.com](http://www.lonza.com)

## Product News

### Further Information

Lonza Ltd  
Scientific Marketing, Nutrition  
Ulla Freitas  
Tel +41 61 316 8273  
Fax +41 61 316 9273  
[ulla.freitas@lonza.com](mailto:ulla.freitas@lonza.com)

Lonza Group Ltd  
Media Relations  
Melanie Disa  
Tel +1 210 316 9413  
Fax +1 201 696 3533  
[melanie.disa@lonza.com](mailto:melanie.disa@lonza.com)